Literature DB >> 30332936

Type 2 diabetes in patients with end-stage kidney disease: influence on cardiovascular disease-related mortality risk.

Wai H Lim1, David W Johnson2, Carmel Hawley2, Charmaine Lok3, Kevan R Polkinghorne4, Matthew A Roberts5, Neil Boudville6, Germaine Wong7.   

Abstract

OBJECTIVES: To examine the association between type 2 diabetes mellitus, with and without diabetic nephropathy, and cardiovascular disease-related mortality in dialysis-dependent patients with end-stage kidney disease (ESKD); to determine whether this association is affected by the age of the patient. DESIGN, SETTING, PARTICIPANTS: Prospective population cohort analysis of Australia and New Zealand Dialysis and Transplant Registry data for all patients with incident ESKD who commenced dialysis in Australia or New Zealand during 1980-2014. OUTCOME MEASURES: Primary outcome: cardiovascular disease-related mortality; secondary outcome: all-cause mortality.
RESULTS: Of 56 552 patients followed for a median 2.5 years (total, 193 549 person-years), 15 829 (28.0%) had type 2 diabetes and diabetic nephropathy; 4993 (8.8%) had type 2 diabetes and non-diabetic nephropathy. Cardiovascular disease-related mortality during the first 10 years of dialysis was significantly higher for patients with diabetes/diabetic nephropathy (277 deaths per 1000 patients; 95% CI, 270-284) or diabetes/non-diabetic nephropathy (220 deaths per 1000 patients; 95% CI, 208-231) than for patients without type 2 diabetes (136 deaths per 1000 patients; 95% CI, 133-140). The risk of cardiovascular disease-related mortality was greater for patients with diabetes/diabetic nephropathy (adjusted hazard ratio [aHR], 1.63; 95% CI, 1.56-1.72) or diabetes/non-diabetic nephropathy (aHR, 1.31; 95% CI, 1.23-1.41) than for patients without diabetes. The excess risk associated with having diabetes was greater for younger than for older patients.
CONCLUSIONS: Mortality risk is higher for patients with incident ESKD commencing dialysis who also have type 2 diabetes than for patients without diabetes, particularly among patients under 50 years of age, and the risk was more pronounced in patients for whom ESKD was attributed to diabetic nephropathy.

Entities:  

Keywords:  Diabetes mellitus, type 2; Kidney diseases; Registries; Renal dialysis

Mesh:

Year:  2018        PMID: 30332936

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  8 in total

1.  Is the use of metformin in patients undergoing dialysis hazardous for life? A systematic review of the safety of metformin in patients undergoing dialysis.

Authors:  Christina Abdel Shaheed; Jane E Carland; Garry G Graham; Sophie L Stocker; Greg Smith; Mark Hicks; Kenneth M Williams; Timothy Furlong; Peter Macdonald; Jerry R Greenfield; Felicity C Smith; Gina Chowdhury; Richard O Day
Journal:  Br J Clin Pharmacol       Date:  2019-12-09       Impact factor: 4.335

2.  Use of the systemic inflammation response index (SIRI) as a novel prognostic marker for patients on peritoneal dialysis.

Authors:  Jiaqi Li; Yingxue Li; Yaowei Zou; Yaode Chen; Lizhen He; Ying Wang; Jingxuan Zhou; Fangqi Xiao; Hongxin Niu; Lingli Lu
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

Review 3.  Cardiovascular disease-related mortality risk in end stage renal disease and type 2 diabetes: A systematic review.

Authors:  Arwa A Al-Hajji; Hibah A Alsubaie; Hanan T Albaqshi; Hayat I Al-Hajji; Fatemah M A AlEssa; Batool M Abu Ali
Journal:  J Family Med Prim Care       Date:  2020-07-30

4.  Diabetes Prevalence, Treatment, Control, and Outcomes Among Hemodialysis Patients in the Gulf Cooperation Council Countries.

Authors:  Saeed M G Al-Ghamdi; Brian Bieber; Mona AlRukhaimi; Ali AlSahow; Issa Al Salmi; Fadwa Al Ali; Ali Al Aradi; Roberto Pecoits-Filho; Bruce M Robinson; Ronald L Pisoni
Journal:  Kidney Int Rep       Date:  2022-02-17

Review 5.  Impact of Metabolic Surgery on Renal Injury in Pre-Clinical Models of Diabetic Kidney Disease.

Authors:  William P Martin; Carel W le Roux; Neil G Docherty
Journal:  Nephron       Date:  2020-12-02       Impact factor: 2.847

6.  Impact of parathyroidectomy among nondiabetic hemodialysis patients with severe hyperparathyroidism.

Authors:  Qing-Xiu Huang; Jie Pang; Chuan-Ke Shi; Xiao-Wen Huang; Xiao-Fang Chen; Yan-Feng Luo; Hai-Wen An; Jian-Lin Jian; Linna Liu; Yan-Lin Li
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

Review 7.  Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.

Authors:  Guntram Schernthaner; Naim Shehadeh; Alexander S Ametov; Anna V Bazarova; Fahim Ebrahimi; Peter Fasching; Andrej Janež; Péter Kempler; Ilze Konrāde; Nebojša M Lalić; Boris Mankovsky; Emil Martinka; Dario Rahelić; Cristian Serafinceanu; Jan Škrha; Tsvetalina Tankova; Žydrūnė Visockienė
Journal:  Cardiovasc Diabetol       Date:  2020-10-23       Impact factor: 9.951

8.  Synergy between the pay-for-performance scheme and better physician-patient relationship might reduce the risk of retinopathy in patients with type 2 diabetes.

Authors:  Shang-Jyh Chiou; Kuomeng Liao; Yu-Tung Huang; Wender Lin; Chi-Jeng Hsieh
Journal:  J Diabetes Investig       Date:  2020-11-07       Impact factor: 4.232

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.